Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Conditions
Metastatic Breast Cancer · ER-positive Breast Cancer · HER2-negative Breast Cancer · Breast Cancer · Locally Advanced Breast Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
University of California San Francisco Health, San Francisco, California, United States
University of Colorado Cancer Center, Aurora, Colorado, United States
Advent Health Hematology and Oncology, Orlando, Florida, United States
University of Iowa, Iowa City, Iowa, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Henry Ford Health, Detroit, Michigan, United States
Regents of the University of Minnesota, Minneapolis, Minnesota, United States
Washington University, School of Medicine, St Louis, Missouri, United States
Ichan School of Medicine at Mount Sinai, New York, New York, United States
Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
Henry-Joyce Cancer Clinic, The Vanderbilt Clinic, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
Northwest Medical Specialties, Tacoma, Washington, United States
Macquarie Health, Sydney, New South Wales, Australia
Breast Cancer Research Center- Western Australia, Nedlands, Western Australia, Australia
Study leads
Daniela Vecchio, PhD
Study Director
Olema Pharmaceuticals, Inc.